Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2004 Dec;96(12):1565–1574.

Economic disparities in treatment costs among ambulatory Medicaid cancer patients.

C Daniel Mullins 1, Stephen E Snyder 1, Junling Wang 1, Jesse L Cooke 1, Claudia Baquet 1
PMCID: PMC2568681  PMID: 15622686

Abstract

BACKGROUND: Cancer is the second leading cause of death in the United States and a major contributor to healthcare expenditure. There are few studies examining disparities in treatment costs. Studies that do exist are dominated by the cost of hospital care. METHODS: Utilizing Maryland Medicaid administrative claims data, a retrospective cohort, design was employed to examine disparities in ambulatory treatment costs of breast, colorectal and prostate cancer treatment by region, race and gender. We report mean and median results by each demographic category and test for the statistical significance of each. Lorenz curves are plotted and Gini coefficients calculated for each type of cancer. RESULTS: We do not find a consistent trend in ambulatory costs across the three cancers by traditional demographic variables. Lorenz curves indicate highly unequal distributions of costs. Gini coefficients are 0.687 for breast cancer, 0.757 for colorectal cancer and 0.774 for prostate cancer. CONCLUSION: Significant variation in nonhospital-based expenditures exists for breast, colorectal and prostate cancers in a population of homogeneous socioeconomic status and uniform insurance entitlement. Observed individual-level disparities are not consistent across cancers by region, race or gender, but the majority of this low-income population receives very little ambulatory care.

Full text

PDF
1565

Images in this article

1571Figure 2
on p.1571

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker M. S., Kessler L. G., Urban N., Smucker R. C. Estimating the treatment costs of breast and lung cancer. Med Care. 1991 Jan;29(1):40–49. doi: 10.1097/00005650-199101000-00004. [DOI] [PubMed] [Google Scholar]
  2. Brown M. L., Lipscomb J., Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001;22:91–113. doi: 10.1146/annurev.publhealth.22.1.91. [DOI] [PubMed] [Google Scholar]
  3. Brown M. L., Riley G. F., Potosky A. L., Etzioni R. D. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care. 1999 Dec;37(12):1249–1259. doi: 10.1097/00005650-199912000-00008. [DOI] [PubMed] [Google Scholar]
  4. Chlebowski R. T., Collyar D. E., Somerfield M. R., Pfister D. G. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol. 1999 Jun;17(6):1939–1955. doi: 10.1200/JCO.1999.17.6.1939. [DOI] [PubMed] [Google Scholar]
  5. Desch C. E., Benson A. B., 3rd, Smith T. J., Flynn P. J., Krause C., Loprinzi C. L., Minsky B. D., Petrelli N. J., Pfister D. G., Somerfield M. R. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol. 1999 Apr;17(4):1312–1312. doi: 10.1200/JCO.1999.17.4.1312. [DOI] [PubMed] [Google Scholar]
  6. Donat S. M., Powell C. T., Israeli R. S., Fair W. R., Heston W. D. Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human prostate cancer cells. J Natl Cancer Inst. 1995 Jan 4;87(1):41–46. doi: 10.1093/jnci/87.1.41. [DOI] [PubMed] [Google Scholar]
  7. Fireman B. H., Quesenberry C. P., Somkin C. P., Jacobson A. S., Baer D., West D., Potosky A. L., Brown M. L. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev. 1997 Summer;18(4):51–76. [PMC free article] [PubMed] [Google Scholar]
  8. Fisher B., Costantino J. P., Wickerham D. L., Redmond C. K., Kavanah M., Cronin W. M., Vogel V., Robidoux A., Dimitrov N., Atkins J. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998 Sep 16;90(18):1371–1388. doi: 10.1093/jnci/90.18.1371. [DOI] [PubMed] [Google Scholar]
  9. Gralla R. J., Osoba D., Kris M. G., Kirkbride P., Hesketh P. J., Chinnery L. W., Clark-Snow R., Gill D. P., Groshen S., Grunberg S. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999 Sep;17(9):2971–2994. doi: 10.1200/JCO.1999.17.9.2971. [DOI] [PubMed] [Google Scholar]
  10. Legorreta A. P., Brooks R. J., Leibowitz A. N., Solin L. J. Cost of breast cancer treatment. A 4-year longitudinal study. Arch Intern Med. 1996 Oct 28;156(19):2197–2201. [PubMed] [Google Scholar]
  11. Mullins C. Daniel, Cooke Jesse L., Jr, Wang Junling, Shaya Fadia T., Hsu Doren Van, Brooks Sandra. Disparities in prevalence rates for lung, colorectal, breast, and prostate cancers in Medicaid. J Natl Med Assoc. 2004 Jun;96(6):809–816. [PMC free article] [PubMed] [Google Scholar]
  12. Rizzo J. Douglas, Lichtin Alan E., Woolf Steven H., Seidenfeld Jerome, Bennett Charles L., Cella David, Djulbegovic Benjamin, Goode Matthew J., Jakubowski Ann A., Lee Stephanie J. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002 Oct 1;20(19):4083–4107. doi: 10.1200/JCO.2002.07.177. [DOI] [PubMed] [Google Scholar]
  13. Roos N. P., Mustard C. A. Variation in health and health care use by socioeconomic status in Winnipeg, Canada: does the system work well? Yes and no. Milbank Q. 1997;75(1):89–111. doi: 10.1111/1468-0009.00045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Schneider Eric C. Measuring mortality outcomes to improve health care: rational use of ratings and rankings. Med Care. 2002 Jan;40(1):1–3. doi: 10.1097/00005650-200201000-00001. [DOI] [PubMed] [Google Scholar]
  15. Smith T. J., Davidson N. E., Schapira D. V., Grunfeld E., Muss H. B., Vogel V. G., 3rd, Somerfield M. R. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol. 1999 Mar;17(3):1080–1082. doi: 10.1200/JCO.1999.17.3.1080. [DOI] [PubMed] [Google Scholar]
  16. Warren Joan L., Brown Martin L., Fay Michael P., Schussler Nicola, Potosky Arnold L., Riley Gerald F. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol. 2002 Jan 1;20(1):307–316. doi: 10.1200/JCO.2002.20.1.307. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES